GH Secretagogues Monitoring Bundle: A Complete Prescriber Reference

What Is the GH Secretagogues Drug Class?

GH secretagogues are peptides or small molecules that amplify endogenous GH pulse amplitude by acting on one of two upstream receptors: the GHRH receptor (stimulated by sermorelin and CJC-1295) or the ghrelin receptor, also called GHS-R1a (stimulated by ipamorelin, GHRP-2, GHRP-6, and the oral agent MK-677/ibutamoren). The two receptor subtypes are pharmacologically distinct, and combining one from each class produces synergistic GH release, which is why ipamorelin/CJC-1295 combinations appear frequently in clinical practice.

Receptor Subtypes and Clinical Relevance

The GHRH-receptor agonists act on somatotrophs directly, mimicking endogenous GHRH. Their GH release is still subject to somatostatin feedback, so physiologic pulsatility is largely preserved. This is clinically meaningful: supraphysiologic IGF-1 is less common with GHRH analogues alone compared with exogenous recombinant GH ([rhGH], which bypasses pulsatile control entirely) [1].

Ghrelin-receptor agonists such as ipamorelin and GHRP-2 work through a separate membrane receptor. Ipamorelin is the most selective agent in this subclass. At standard doses (100 to 300 mcg subcutaneous), it produces minimal co-secretion of ACTH, cortisol, or prolactin, a selectivity profile confirmed in a controlled trial by Raun et al. [2]. GHRP-2 and GHRP-6 are substantially less selective. Both raise ACTH and cortisol measurably, and GHRP-6 stimulates ghrelin-mediated appetite enough to complicate weight management goals [3].

MK-677: The Oral Outlier

MK-677 (ibutamoren) is a non-peptide, orally active ghrelin mimetic. The AGHD-trial data from Copinschi et al. (N=24, cross-over) demonstrated sustained GH and IGF-1 elevation over 2-year exposure at 25 mg/day [4]. Because MK-677 raises fasting insulin and can increase fasting glucose in both healthy adults and individuals with pre-existing insulin resistance, glucose monitoring is non-negotiable on this agent [5]. The Healthy Aging and Body Composition (Health ABC) trial using 25 mg MK-677 daily in 65-year-old adults (N=395) recorded a statistically significant increase in fasting glucose (P<0.05) and a higher rate of new-onset or worsened glucose intolerance compared with placebo [5].

Baseline Evaluation Before Starting Any GH Secretagogue

Every prescriber should obtain a minimum dataset before the first dose. Ordering labs after starting therapy makes it impossible to distinguish drug effect from pre-existing pathology.

Required Baseline Lab Panel

| Lab | Rationale | Reference Range Note | |---|---|---| | Serum IGF-1 | Primary efficacy and safety biomarker | Use age- and sex-matched reference intervals | | Fasting glucose | Detect pre-diabetes before GH-mediated insulin resistance | ADA threshold: ≥100 mg/dL = impaired fasting glucose [6] | | HbA1c | 3-month glucose average; MK-677 risk stratification | ADA threshold: ≥5.7% = pre-diabetes [6] | | Fasting insulin / HOMA-IR | Quantifies baseline insulin resistance | HOMA-IR >2.5 warrants caution on MK-677 | | Cortisol (AM, fasting) | Baseline before GHRP-2/GHRP-6 which raise ACTH | Collect 7 to 9 AM | | Prolactin | Baseline before non-selective GHRPs | Mild elevations can occur | | Comprehensive metabolic panel | Hepatic and renal function affect peptide clearance | Standard | | Lipid panel | GH physiology alters lipoprotein metabolism | Fasting specimen | | TSH | Hypothyroidism blunts GH axis response | Free T4 if TSH abnormal |

The Endocrine Society's 2011 clinical practice guideline on adult GH deficiency states: "Serum IGF-1 measured with a reliable, validated assay normalized for age and sex is the primary biochemical monitoring parameter during GH therapy." [7] The same standard applies to secretagogue-stimulated GH elevation, because the downstream biomarker is identical regardless of whether GH originates from exogenous injection or endogenous pulse augmentation.

Imaging and History Screening

Obtain a thorough personal and family history of pituitary tumors, acromegaly, or multiple endocrine neoplasia (MEN-1) before prescribing. GH secretagogues are contraindicated in active malignancy because IGF-1 is a mitogenic signal. One meta-analysis (N=26 studies) found serum IGF-1 above the upper quartile of normal was associated with modestly increased risk of colorectal, prostate, and breast cancers, though causality in short-term secretagogue use is not established [8]. The FDA's guidance on IGF-1 excess risk is incorporated into prescribing information for approved somatropin products and represents the closest regulatory analogy [9].

On-Therapy Monitoring Schedule

Structure follow-up around dose changes, not calendar dates. IGF-1 lags GH changes by roughly 3 to 4 weeks, so checking at 6 to 8 weeks after any dose adjustment gives a stable steady-state reading.

The 4-Week Check (Weeks 3 to 5)

At the first follow-up, focus on tolerability rather than efficacy biomarkers.

• Ask about water retention, peripheral edema, paresthesias, and morning stiffness. These are the same fluid-retention side effects documented with recombinant GH and occur via the same renal tubular sodium-reabsorption mechanism [10].
• For patients on GHRP-2 or GHRP-6: check AM cortisol. A cortisol value above 20 mcg/dL in a patient with new anxiety, insomnia, or palpitations should prompt a switch to ipamorelin or a dose reduction before continuing.
• Check fasting glucose if baseline was 90 to 99 mg/dL (borderline) or if the patient uses MK-677.

The 6-to-8-Week IGF-1 Check

This is the primary titration visit. Compare the new IGF-1 to the age-matched mid-normal reference. The Endocrine Society defines optimal IGF-1 during GH therapy as "a value in the mid-normal range for the patient's age and sex, approximately the 50th to 75th percentile." [7]

Titration decision tree:

1. IGF-1 <25th percentile: dose is sub-therapeutic; increase by one increment (e.g., add 50 mcg to the ipamorelin evening dose).
2. IGF-1 25th to 75th percentile: target achieved; continue current dose.
3. IGF-1 75th to 97th percentile: dose is at the upper edge; consider reducing, especially in patients over 60 or those with active cardiovascular disease.
4. IGF-1 above the age-matched upper reference limit on two consecutive checks: discontinue. This threshold is not arbitrary. The KIMS observational database of 13,983 GH-treated adults found that IGF-1 persistently above +2 SD correlated with higher rates of edema, arthralgia, and carpal tunnel syndrome [11].

Quarterly Monitoring (Months 3, 6, 9, 12)

Once IGF-1 is stable in the target range, quarterly visits cover:

• Serum IGF-1
• Fasting glucose and HbA1c (every 6 months, or quarterly for MK-677 users)
• Blood pressure (GH raises fluid retention and can mildly raise systolic BP)
• Body composition assessment if available (DEXA or BIA every 6 months)
• Review of symptoms: paresthesias, joint pain, sleep quality, and libido

Annual labs should add: full lipid panel, AM cortisol (for those on non-selective GHRPs), prolactin, and CMP.

Agent-Specific Monitoring Considerations

Ipamorelin and CJC-1295 (The Most Common Combination)

The ipamorelin/CJC-1295 combination is the most frequently prescribed pairing in the compounded peptide market. Ipamorelin provides selective GHS-R1a stimulation; CJC-1295 (with DAC, drug affinity complex) provides prolonged GHRH-receptor stimulation with a half-life of approximately 8 days after subcutaneous injection [12]. The extended half-life of CJC-1295 with DAC means weekly or twice-weekly dosing is feasible, but it also means that if IGF-1 overshoots, the prescriber cannot quickly reverse the effect by withholding doses. For this reason, starting CJC-1295 at the lower licensed compounding dose (1 to 2 mg/week) and titrating in 0.5 mg increments is safer than starting at the maximum.

Ipamorelin-specific monitoring is straightforward: cortisol and prolactin elevation is rare at doses under 300 mcg. Monitoring for glucose dysregulation is low priority unless the patient has pre-existing insulin resistance. Sleep-onset dosing (30 minutes before sleep) captures the natural nocturnal GH surge and produces the best IGF-1 response per dose.

GHRP-2 and GHRP-6

Both agents stimulate ACTH release in a dose-dependent manner. A pharmacodynamic study by Arvat et al. (N=10, healthy men, intravenous GHRP-2 at 1 mcg/kg) showed cortisol increased by a mean of 8.2 mcg/dL above baseline within 60 minutes [3]. In patients with adrenal fatigue histories or concurrent HPA-axis stress, this can produce clinically apparent symptoms. Repeat AM cortisol at 4 weeks. If cortisol exceeds 22 mcg/dL on two morning draws, reduce dose or switch to ipamorelin.

GHRP-6 carries the additional complication of significant appetite stimulation. Patients seeking body composition improvement may paradoxically gain fat mass if caloric intake is not controlled. Appetite symptom logging at every visit is simple and informative.

Sermorelin

Sermorelin is a truncated 29-amino-acid analogue of endogenous GHRH. Its short half-life (approximately 10 to 20 minutes) makes it the most physiologically conservative option. The FDA approved sermorelin acetate (Geref) for pediatric GH deficiency in 1997 before withdrawing the product for commercial rather than safety reasons [13]. IGF-1 response with sermorelin monotherapy in adults is modest. Titration and monitoring intervals are the same as for CJC-1295, but the 8-week IGF-1 check may show only a 10 to 20% increase from baseline versus the 40 to 60% increase typical with ipamorelin/CJC-1295 combinations.

MK-677 (Ibutamoren)

MK-677 requires a dedicated glucose monitoring track. At the 25 mg/day dose used in the Health ABC trial, fasting glucose increased by a mean of 4 to 5 mg/dL and insulin sensitivity decreased measurably [5]. For patients with BMI >27 or baseline HbA1c ≥5.7%:

• Check HbA1c every 3 months for the first year.
• Check fasting glucose monthly for months 1 to 3, then quarterly.
• Consider metformin co-prescription if HbA1c reaches 6.0% on therapy.

MK-677 also elevates prolactin in some users. Check prolactin at 4 and 12 weeks. Prolactin above 25 ng/mL in a male patient warrants a dose reduction to 12.5 mg/day before considering discontinuation.

Dose Titration Principles

GH secretagogue titration is not one-size-fits-all. Age, sex, body composition, and baseline IGF-1 all influence the starting dose and titration rate.

Age-Adjusted Dosing

IGF-1 reference ranges decline with age. A 35-year-old with an IGF-1 of 180 ng/mL may be at the 50th percentile for their age group, while the same value in a 65-year-old is above the 75th percentile. Always interpret absolute IGF-1 values against the laboratory's age-matched normative data, not a single universal threshold.

Older adults (over 60) produce less somatostatin-mediated feedback, which paradoxically can make them more sensitive to secretagogues. Start at 50% of the standard dose and titrate more slowly, with 10-week IGF-1 rechecks rather than 6-week.

Sex Differences in GH Axis Response

Women have higher basal GH pulse frequency and amplitude than men of the same age due to estrogen effects on somatotroph sensitivity [14]. Women on estrogen therapy (oral especially) may need higher secretagogue doses to achieve the same IGF-1 increment because oral estrogen induces hepatic IGF-1 production less efficiently than transdermal estrogen [14]. This is a frequently overlooked interaction. For women on oral estradiol, consider switching to transdermal formulations before concluding that a GH secretagogue is inadequate.

Cycling vs. Continuous Dosing

No randomized controlled trial has directly compared continuous versus cycled secretagogue therapy in healthy adults. The physiologic rationale for cycling comes from data showing that continuous exogenous GHRH infusion downregulates pituitary GHRH receptors within weeks [1]. Common clinical practice involves 5-days-on/2-days-off weekly cycles or 3-months-on/1-month-off cycles. Until RCT data exist, the 5/2 weekly cycle is pragmatically reasonable and avoids the compliance complexity of monthly on-off schedules.

Safety Signals and Discontinuation Criteria

Absolute Discontinuation Criteria

Stop GH secretagogue therapy immediately if any of the following occur:

• New diagnosis of active malignancy (any type).
• IGF-1 above age-matched upper reference limit on two consecutive 8-week checks despite dose reduction.
• Symptomatic carpal tunnel syndrome unresponsive to conservative management.
• HbA1c exceeding 7.0% on MK-677 that does not respond to dose halving within 12 weeks.
• Intracranial hypertension symptoms (severe headache, visual changes, papilledema).

Relative Discontinuation / Dose Reduction Criteria

Consider stopping or substantially reducing dose when:

• Fasting glucose rises above 100 mg/dL from a sub-100 mg/dL baseline.
• Edema is present on physical exam without an alternative explanation.
• Patient develops or worsens sleep apnea. GH promotes soft-tissue hypertrophy that can worsen upper airway obstruction. This is a documented side effect of rhGH therapy [10] and is biologically plausible with secretagogue-augmented GH.
• Prolactin exceeds 25 ng/mL (male) or 30 ng/mL (female, non-pregnant) on two consecutive checks.

Drug Interactions and Concurrent Therapy

GH secretagogues are commonly co-prescribed with testosterone replacement therapy, thyroid hormone, or exogenous insulin. Each pairing creates a monitoring consideration.

Testosterone elevates IGF-1 through hepatic sensitization. A patient starting both TRT and ipamorelin/CJC-1295 simultaneously will have two variables driving IGF-1 upward. Start one agent at a time, or if starting concurrently, set the 6-week IGF-1 recheck as a mandatory visit rather than optional.

Thyroid hormone deficiency suppresses the GH axis. If a patient shows a blunted IGF-1 response to adequate secretagogue dosing, check TSH and free T4 before concluding the secretagogue is ineffective. The Endocrine Society guideline notes that hypothyroidism reduces GH secretion and impairs IGF-1 generation independently [7].

Glucocorticoids suppress GH axis function at every level: they reduce GHRH secretion, increase somatostatin tone, and reduce hepatic IGF-1 production. Patients on chronic prednisone (even low-dose 5 mg/day) will likely show blunted secretagogue responses. This is not a reason to escalate secretagogue dose reflexively; address glucocorticoid burden first.

Regulatory and Compounding Context

The FDA has not approved any GH secretagogue peptide for adult body composition or anti-aging indications. Sermorelin acetate carries historical FDA approval for pediatric GH deficiency (NDA 019886) [13]. CJC-1295, ipamorelin, GHRP-2, GHRP-6, and MK-677 are available only through compounding pharmacies in the United States under 503A or 503B designations, or as research chemicals.

In November 2023, the FDA finalized guidance placing several bulk drug substances, including ipamorelin and CJC-1295, on the list of substances that may be used in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act, subject to specific conditions [9]. Prescribers should verify that their compounding pharmacy holds current USP <797> sterile compounding accreditation and provides certificates of analysis (COA) confirming peptide identity, purity, and endotoxin testing for every batch.

MK-677 is not currently eligible for compounding under 503A or 503B because it is not a peptide. Prescribers should be aware that oral MK-677 sold through research chemical vendors is not subject to pharmaceutical manufacturing standards and carries unknown purity and dosing consistency.

Summary Monitoring Schedule (Quick Reference)

| Timepoint | Labs | Clinical Check | |---|---|---| | Baseline (before dose 1) | IGF-1, fasting glucose, HbA1c, fasting insulin, AM cortisol, prolactin, CMP, lipids, TSH | History, exam, contraindication screen | | Week 4 | Fasting glucose (MK-677 or borderline baseline); AM cortisol (GHRP-2/6) | Tolerability: edema, paresthesias, sleep | | Weeks 6 to 8 | IGF-1; fasting glucose if MK-677 | Dose titration decision | | Month 3 | IGF-1, fasting glucose, HbA1c (MK-677) | BP, symptom review | | Month 6 | IGF-1, fasting glucose, HbA1c, prolactin (if GHRP or MK-677) | DEXA or BIA if available | | Month 12 | Full panel: all baseline labs repeated | Annual reassessment; consider 1-month drug holiday | | Any dose change | IGF-1 at 6 to 8 weeks post-change | Re-titrate per algorithm above |

The 6-to-8-week post-titration IGF-1 check is the single most important recurring test in this monitoring bundle. Adherence to that interval separates safe secretagogue prescribing from the unmonitored off-label use that generates adverse-event case reports.